BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $488,754 | +61.3% | 69,033 | +187.2% | 0.01% | +11.1% |
| Q3 2022 | $303,000 | +27.8% | 24,034 | +65.2% | 0.01% | +28.6% |
| Q1 2022 | $237,000 | +51.0% | 14,548 | +28.7% | 0.01% | +40.0% |
| Q4 2021 | $157,000 | -79.6% | 11,308 | -76.8% | 0.01% | -84.8% |
| Q2 2021 | $769,000 | +605.5% | 48,641 | +231.8% | 0.03% | +725.0% |
| Q4 2020 | $109,000 | +127.1% | 14,658 | +5.0% | 0.00% | +100.0% |
| Q3 2020 | $48,000 | -33.3% | 13,964 | -7.8% | 0.00% | 0.0% |
| Q2 2020 | $72,000 | +26.3% | 15,140 | -46.6% | 0.00% | 0.0% |
| Q1 2020 | $57,000 | -94.6% | 28,368 | -77.6% | 0.00% | -84.6% |
| Q1 2017 | $1,063,000 | +431.5% | 126,553 | +551.5% | 0.01% | +550.0% |
| Q4 2015 | $200,000 | – | 19,424 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |